China Council for the promotion of drugs launched the evaluation of special achievements of major new drug development entrusted by the science and Education Department of the health and Family Planning Commission

Source: China Council for the promotion of drugs 2016-4-9 since the national implementation of "major new drug creation" science and technology major project (hereinafter referred to as "major project") in 2008, during the "11th Five Year Plan" and "12th Five Year Plan", 136 Billion yuan is used to support pharmaceutical innovation, accelerating the strategic transformation of China's pharmaceutical industry from imitation to creation In order to implement the innovation driven development strategy and the spirit of science and technology system reform, the science and Technology Education Department of the national health and Family Planning Commission (hereinafter referred to as "the science and Education Department of the health and Family Planning Commission") entrusted the China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "the China pharmaceutical promotion association") in March 2016 to carry out a third-party evaluation on the implementation effect of 1595 projects supported by the special implementation of new drug science and technology The evaluation will focus on the role played by the implementation of the project in improving the innovation ability of China's pharmaceutical industry, meeting major clinical needs, realizing clinical substitution, promoting technology upgrading and other aspects, as well as the economic and social benefits achieved In order to make the evaluation fair, scientific and objective, the China Council for the promotion of drugs has set up a major special evaluation office (hereinafter referred to as the special evaluation office) Through the strict selection of chemical medicine, traditional Chinese medicine and biological medicine research experts, a major special evaluation expert team covering the fields of pharmaceutical chemistry, pharmacological efficacy and clinical research has been established, and the "major new drug creation" has been formulated Measures for the administration of evaluation of major scientific and technological projects and the standard for the evaluation of major scientific and technological projects of "major new drug creation", and an evaluation index system based on objective data has been established In this assessment, the output of major special implementation results and some representative key projects will be evaluated by holding enterprise report and expert review meeting, conducting enterprise field survey and other methods After nearly a month of intense preparation, the major special expert review conference was held in Beijing on the morning of April 9, with more than 30 experts participating in the meeting, which marks the start of the major special evaluation of the drug promotion commission Photos of Han JUANJUAN, leader of science and Education Department of health and Family Planning Commission, Jiang Hualiang, President of pharmaceutical promotion association and song Ruilin